Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Medicines defect alert issued for Syonell 250mg, 500mg gastro-resistant tablets

The Medicines and Health products Regulatory Agency (MHRA) has issued a class four medicines defect alert for Syonell 250mg & 500mg gastro-resistant tablets of Lupin Healthcare (UK) Limited.

Lupin has informed the health regulator of a discrepancy with the product packaging for several batches of Syonell 250mg Gastro-Resistant Tablets and Syonell 500mg Gastro-Resistant Tablets.


This discrepancy relates to the incorrect amount of active pharmaceutical ingredient-valproate semisodium printed on the outer packaging.

Labelling on the current packagingCorrect labelling on the packaging 
Syonell 250mg Gastro-Resistant Tablets each gastro-resistant tablet contains 250mg of valproate semi sodiumSyonell 250mg Gastro-Resistant Tablets each gastro-resistant tablet contains 269.06mg of valproate semisodium equivalent to 250mg of valproic acid
Syonell 500mg Gastro-Resistant Tablets each gastro-resistant tablet contains 500mg of valproate semi sodiumSyonell 500mg Gastro-Resistant Tablets each gastro-resistant tablet contains 538.12mg of valproate semisodium equivalent to 500mg of valproic acid

The amounts of active pharmaceutical ingredient are stated correctly in the respective Patient Information Leaflets (PIL) and Summary of Product Characteristics (SmPCs).

Syonell 250mg Gastro-Resistant Tablets with PL 35507/0191

Batch NumberExpiry DatePack SizeFirst Distributed
G908002Sep – 213006/01/2020
G908614Oct – 213008/04/2020
G908561Oct -213020/03/2020
G003139Mar- 223018/06/2020
G003899Apr- 223025/09/2020
G003900Apr- 223005/10/2020
G003901Apr- 223004/02/2021

The following batches have been packed and are awaiting distribution

Batch NumberExpiry DatePack SizeFirst Distributed
G004456May-2230
G004457May-2230

Syonell 500mg Gastro-Resistant Tablets PL 35507/0192

Batch NumberExpiry DatePack SizeFirst Distributed
G908002Sep – 213027/12/2019
G908441Oct – 213009/03/2020
G908835Oct -213015/03/2020
G000647Dec – 213020/03/2020
G000648Dec – 213005/04/2020
G002361Feb – 223011/05/2020
G002362Feb – 223012/05/2020
G002363Dec- 213028/05/2020
G002901Mar -223018/06/2020
G004160Apr – 223024/09/2020
G004161Apr – 223027/09/2020
G004168Apr – 223026/10/2020
G004169Apr – 223008/12/2020
G004170Apr – 223001/02/2021
G004171Apr – 223009/03/2021
G004931May – 223011/01/2021

The following batches have been packed and are awaiting distribution

Batch NumberExpiry DatePack SizeFirst Distributed
G004936May-2230
G004938May-2230
G004940May-2230
G004941May-2230
G004932May-2230
G004933May-2230

The MHRA further added that, the healthcare professionals are advised to exercise caution when dispensing the product. There is no risk to product quality as a result of this issue, therefore the affected batches are not being recalled.

More For You

Students from retail sector using bursary aid for postgraduate education

The charity has given £28 million worth of financial aid to postgraduate students.

Bursary applications open for pharmacy students

A leading charity that provides financial aid for the families of those working in the pharmacy, convenience and grocery sector, has announced postgraduate bursary applications open for 2025/2026.

The Leverhulme Trade Charities Trust (LTCT) bursary scheme is open to students on postgraduate courses, whose parent, carer, spouse is employed in an eligible profession, such as convenience retailer, supermarket store worker, or pharmacy technician.

Keep ReadingShow less
The NHS has changed payment structure for consultations

The NHS has changed payment structure for consultations

Maximising new medicine services can be a game changer for pharmacists

Adele Curran, chief operations officer at RWA Pharmacy Ltd, looks at the changes to NMS and the financial opportunities they offer for Community Pharmacies

English pharmacies have been delivering new medicine services (NMS) since October 2011. They have successfully increased the effective use of medicines across their communities and also increased their revenue through the claiming structure.

Keep ReadingShow less
Camizestrant Cuts Breast Cancer Progression by 50% – New Hope

There was a 56 per cent reduction in the risk of disease progression or death

Pic credit: iStock

Blood test-guided treatment with AstraZeneca pill cuts breast cancer progression risk

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death by half, a finding that could be practice changing, experts said on Sunday.

The results, presented at the American Society of Clinical Oncology meeting in Chicago, mark the first use of a blood test called a liquid biopsy to indicate the need for a change in treatment in women with a common form of breast cancer, even before tumor growth can be detected on imaging.

Keep ReadingShow less
medicine stock shortage

Creon is used in pancreatic cancer patients to help digest food

Pic credit: iStock

Patients lives being put at risk due to ‘worst stock shortage’, warns pharmacists

Cancer patients are skipping meals in order to ration a vital medicine that has been difficult to get hold of due to ongoing shortages.

Pharmacists have warned of the struggles they are facing to source Creon - a pancreatic enzyme replacement therapy (PERT), which helps people living with conditions such as cystic fibrosis, pancreatitis, and pancreatic cancer to digest food.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

Acute sore throats had the most consultations

Pic credit: istock

Pharmacy First has already seen over five million patients

The Pharmacy First scheme has helped over five million patients with minor illnesses, according to NHS England.

Around 2.4 million people received help without booking an appointment at their local pharmacy for seven common conditions including sore throat, earache or shingles.

Keep ReadingShow less